We set up the MSF Access Campaign in 1999 to push for access to, and the development of, life-saving and life-prolonging medicines, diagnostic tests and vaccines for people in our programmes and beyond.

Based in Brussels, MSF Analysis intends to stimulate reflection and debate on humanitarian topics organised around the themes of migration, refugees, aid access, health policy and the environment in which aid operates.

Our medical guidelines are based on scientific data collected from MSF’s experiences, the World Health Organization (WHO), other renowned international medical institutions, and medical and scientific journals.

Evaluation Units have been established in Vienna, Stockholm, and Paris, assessing the potential and limitations of medical humanitarian action, thereby enhancing the effectiveness of our medical humanitarian work.

Providing epidemiological expertise to underpin our operations, conducting research and training to support our goal of providing medical aid in areas where people are affected by conflict, epidemics, disasters, or excluded from health care.

A collaborative, patients’ needs-driven, non-profit drug research and development organisation that is developing new treatments for neglected diseases, founded in 2003 by seven organisations from around the world.

First-ever study of HIV treatment policies in 23 countries

First-ever study of HIV treatment policies in 23 countries

Speed Up Scale Up: Strategies, tools and policies to get the best HIV treatment to more people, soonerpdf — 2.05 MBDownload

Washington, DC - A first-of-its-kind study released today by Médecins Sans Frontières (MSF) maps progress across 23 countries on HIV treatment strategies, tools and policies needed to increase treatment scale-up. The results show that governments have made improvements to get better antiretroviral (ARV) treatment to more people, but implementation of innovative community-based strategies is lagging in some countries.

The study, a collaboration with UNAIDS, looked at 25 indicators in each country, ranging from coverage of ARV treatment and prevention of mother-to-child transmission (PMTCT), to whether nurses instead of doctors can start patients on HIV and TB treatment - critical to relieving the burden on health systems and to getting treatment further into communities - and how many health facilities in each country offer ARV treatment.

“What we’re seeing is that governments are working to get better HIV medicines to their people, and to provide treatment closer to home so that more people can benefit,” said Sharonann Lynch, HIV Policy Advisor for MSF’s Access Campaign. “But there’s still a long way to go. More countries need to shift policies to allow nurses to start people on treatment, and other health workers to monitor patients’ treatment so treatment can be available in every clinic, in every village, in every country struggling with HIV.”

A new model of patient care

Main findings of the study include:

Eleven of 23 countries have reached ARV treatment coverage of 60 per cent or more, while six are still reaching only one third of people in need.

Six countries have PMTCT coverage rates over 80 per cent, while eight are still below 50 per cent, with five of these below 30 per cent.

Only eight of the 20 countries for which data was available provide ARV treatment in 30 pre cent or more of their health facilities, while in countries like Lesotho, Malawi and South Africa where over 60 per cent of health facilities offer ARV treatment, treatment coverage is greater, at over 50 per cent.

Of the 18 sub-Saharan African countries in the study, 11 allow nurses to start patients on ARV treatment, with Kenya, South Africa, Swaziland, Uganda, Zambia and Zimbabwe having changed their policies just in the last two years to allow this. Mozambique is the country with the highest HIV prevalence of the countries in the study to still not allow basic nurses to initiate and manage ARV treatment.

Further, all countries in the survey had adopted WHO-recommended better-tolerated ARVs, and ARV treatment initiation at 350 CD4 cell count, although implementation in some countries lag due to funding shortfalls.

Of the 23 countries surveyed, only four have access to viral load monitoring.

“One of the biggest questions being posed at the international AIDS conference this year is whether it will be feasible to reach the number of people in need of treatment in order to start reversing the epidemic,” said Dr Tom Decroo of MSF in Mozambique. “There's a lot of talk about efficiencies at this conference, but we have to make sure the patient doesn’t get lost in this discussion. Moving treatment down to the community level means the interest of patients and health systems overlap. We’re showing that we can take HIV care out of hospitals and keep people healthy while making life easier for patients and easing the strain on the health system. We’re starting to move toward a model of patient care similar to that of chronic disease management in developed countries.”

Community-based models of treatment

MSF has implemented treatment models that put people at the centre of their care, such as in Tete, Mozambique, where neighbours gather in groups of six and take turns collecting medicine refills for the group; or ‘adherence clubs’ in Khayelitsha, where stable patients receive treatment from adherence counsellors in groups of 20, where the whole group can be done with a checkup in under two hours; or in the Democratic Republic of the Congo, where people living with HIV manage HIV drug distribution directly in the community. These models are outlined in the new MSF and UNAIDS report, Closer to Home.

Better tools to get ahead of the wave of new infections are equally critical. All countries in the survey have shifted policies to provide better-tolerated ARVs to people - although implementation can depend on availability of funding. But only four of the countries in the survey have access to viral load testing, which is the gold standard in treatment monitoring, and routine in developed countries.

“I am one of eight million people living with HIV who have access to life-saving treatment,” said Charles Sako, who works in MSF’s clinic outside of Nairobi, Kenya. “But for every person like me, there is one more person who doesn’t have the medicines they need to stay alive. We must not tire in pushing governments to implement the best strategies, tools and policies to get treatment to as many people as possible, as fast as possible. And we must appeal to all donors to keep supporting this vital global effort.”

HIV/AIDS

Closer to Home: Delivering antiretroviral therapy in the community

Report25 Jul 2012

MSF currently provides HIV treatment to 220,000 people in 23 countries.

Find out more about MSF's activities at the International AIDS Conference 2012 on the MSF at IAC site.

Related

HIV/AIDS

Closer to Home: Delivering antiretroviral therapy in the community

Report25 Jul 2012

Zimbabwe

"We cannot normalise a situation that is not normal"

Voices from the Field21 Dec 2012

Access to medicines

Medicines shouldn't be a luxury

Project Update19 Dec 2012

Up Next

HIV/AIDS

Closer to Home: Delivering antiretroviral therapy in the community

Report25 July 2012

How your donations are used

Your donations pay for millions of consultations, surgeries, treatments and vaccinations every year.